A Global Approach to Tackle Cognitive Decline

The number of people suffering from dementia in Asia (22.9 million) is more than twice the numbers in Europe (10.5 million) or the Americas (9.4 million), as recorded in the global impact of dementia in the World Alzheimer Report 2015.1 This dementia tsunami will continue to rise and the estimated number is 67 million in 2050 in Asia alone, which will be 2 to 3 times higher than the estimates for Europe (19 million) or the Americas (30 million). Devising and implementing preventive strategies against dementia is of paramount importance. The proposed project will be able to establish the associations between VRFs and cognition across cohorts with cultural, ethnical, and demographical variations. This study will generate data for evidence-based knowledge for globally implementable and effective preventive strategies for cognitive impairment and dementia.

Study Overview

• Status: Active, not recruiting
• Conditions: Dementia

Detailed Description

Participants will be retrospectively selected from a Hong Kong Chinese cohort, a Singaporean cohort, a British cohort, two European cohorts, and an Australian cohort.

Subjects from the above listed cohorts who fit the study criteria will be selected for this study.

Demographical information, clinical, vascular risk factors, MRI images and cognitive data will be retrieved from the cohorts.

• Study Type: Observational
• Enrollment (Actual): 1502

Contacts and Locations

Study Locations

• Hong Kong
  • N.t.
    • Shatin, N.t., Hong Kong, 00000
      • Prince of Wales Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Subjects will be retrospectively selected from 7 cohorts from Hong Kong, Australia, Singapore and Europe areas.

Description

Inclusion Criteria:

1. Elderly community-dwelling individuals aged over 60 years old;
2. those with at least 2 time points of detailed cognitive measurements, with 2-3 years of assessment interval;
3. with at least 1 timepoint of MRI (T1, FLAIR, and DTI).

Exclusion Criteria:

1. subjects with stroke, dementia, and other neurological diseases at baseline;
2. those without longitudinal cognitive data;
3. those without MRI data available.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Record of any vascular risk factors	medical history of hypertension, diabetes mellitus, hyperlipidemia, smoking and drinking, record unit as yes or no	Baseline
Record of triglyceride level	triglyceride level, as one of vascular risk factors, unit as mmol/L	Baseline
Record of high-density-lipoprotein level,	high-density-lipoprotein level, as one of the vascular risk factors, unit as mmol/L	Baseline
Record of low-density-lipoprotein level,	low-density-lipoprotein level, as one of the vascular risk factors, unit as mmol/L	Baseline
Record of total cholesterol level,	total cholesterol level, as one of the vascular risk factors, unit as mmol/L	Baseline
Record of glycated hemoglobin	glycated hemoglobin, as one of the vascular risk factors, unit as percentage	Baseline
Record of fasting blood glucose	fasting blood glucose from blood results, as one of vascular risk factors, unit as mmol/L	Baseline
Record of blood pressure	Blood pressure, as one of vascular risk factors, unit as mmHg	Baseline
Record of pulse	Pulse rate, as one of vascular risk factors, unit as bpm	Baseline
Change of Mini-Mental State Examination	Mini-Mental State Examination is used for measuring general cognition including the domains of attention and processing speed, executive function, memory, visuospatial function, and animal fluency.	Baseline and 3rd year follow up
Change of Montreal Cognitive Assessment	Montreal Cognitive Assessment is used for measuring general cognition including the domains of attention and processing speed, executive function, memory, visuospatial function, and animal fluency.	Baseline, 1 yr, 2yr and 3rd year follow ups
Changes of brain white matter abnormalities	brain white matter abnormalities can be observed through the FLAIR sequence of brain MRI images	Baseline and 1 yr, 2yr and 3rd year follow ups

Collaborators and Investigators

• Sponsor: Chinese University of Hong Kong
• Collaborators: University College, London; University of Oxford; Umeå University; The University of New South Wales; Max Planck Institute for Human Development; National University of Singapore
• Investigators: Principal Investigator: Bonnie Yin Ka Lam, Chinese University of Hong Kong

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2022
• Primary Completion (Estimated): May 1, 2025
• Study Completion (Estimated): October 1, 2025

Study Registration Dates

• First Submitted: May 18, 2022
• First Submitted That Met QC Criteria: July 26, 2022
• First Posted (Actual): July 29, 2022

Study Record Updates

• Last Update Posted (Actual): February 15, 2024
• Last Update Submitted That Met QC Criteria: February 13, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Neurocognitive Disorders; Cognition Disorders; Cognitive Dysfunction
• Other Study ID Numbers: 2022.119

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No